pharmaceuticals
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread |
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study |
Covid-19 Has Turned Public Health Into a Lethal, Patient-Killing Experimental Endeavor |
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study |
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19? |
Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19) |
Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients |
Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis |
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France |
HCQ for COVID-19: 412 studies from 8,590 scientists 529,060 patients in 58 countries |
HCQ for COVID-19: real-time meta analysis of 412 studies |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial |
Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients |
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis (RETRACTED) |
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |
Ivermectin Could Have Saved Millions of Lives, Why Was It Suppressed |
Open Knowledge Commons versus Privatized Gain in a Fractured Information Ecology: Lessons from COVID-19 for the Future of Sustainability |
Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients |
Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities |
Role of hydroxychloroquine in multidrug treatment of COVID-19 |
Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial |
Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2 |
Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards |
WHO advises that ivermectin only be used to treat COVID-19 within clinical trials |